|
Abstract
|
RRECTED
CA125is aMucinglycoprotein andits concentration in humanserumcorrelates withawoman'sriskofde-
veloping ovarian cancerandalsoindicatesresponseto therapyin diagnosedpatients. Accurate detection of
this large, complexprotein in patient biofluids is ofgreatclinicalrelevance.In this work,aninnovative im-
munoassay for quantitation ofCA125basedonsignalamplification strategy wasproposed.In this work,
Horseradishperoxidase(HRP)labeledCA125-antibody(anti-CA125)wasimmobilized ontoagreenandbio-
compatiblenanocompositecontainingpolycetyltrimethyl ammoniumbromide(P(CTAB) asconductivema-
trix, chitosan(CS)asbiocompatibleagentandslivernanoparticles(Ag NPs)assignalamplification element.
Therefore,anovelnanocomposite film basedP(CTAB-CS)andAgNPswasexploitedto developahighly
sensitive immunosensorfordetection ofCA125protein. Importantly, AgNPspreparedbyelectrodeposition
methodwhichlead to compactmorphology.Fullyelectrochemicalmethodologywasusedto prepareanew
transduceronaglassycarbonsurfacewhichprovidedahighsurfaceareato immobilize ahighamountofthe
anti-CA125.Thesurfacemorphologyofelectrode wascharacterized byhigh-resolution field emissionscan-
ningelectronmicroscope(FE-SEM)andenergydispersivespectroscopy (EDS). Theimmunosensorwasem-
ployedforthe detection ofCA125usingcyclicvoltammetry (CV)anddifferentialpulsevoltammetry (DPVs)
techniques.Underoptimizedcondition the calibration curveforCA125concentration bySWVandDPVwas
linearin 0.01–400U/mLwithlower limit ofquantification of0.001U/mL.Themethodwassuccessfullyap-
pliedassayofthe CA125in unprocessedhumanplasmasamples.
|